JP2019506159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506159A5 JP2019506159A5 JP2018538551A JP2018538551A JP2019506159A5 JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5 JP 2018538551 A JP2018538551 A JP 2018538551A JP 2018538551 A JP2018538551 A JP 2018538551A JP 2019506159 A5 JP2019506159 A5 JP 2019506159A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- factor
- complement factor
- aptamer according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022039070A JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281092P | 2016-01-20 | 2016-01-20 | |
| US62/281,092 | 2016-01-20 | ||
| US201662297095P | 2016-02-18 | 2016-02-18 | |
| US62/297,095 | 2016-02-18 | ||
| PCT/US2017/014458 WO2017127761A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for inhibiting factor d |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Division JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Division JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506159A JP2019506159A (ja) | 2019-03-07 |
| JP2019506159A5 true JP2019506159A5 (enExample) | 2020-02-27 |
Family
ID=59362699
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538551A Pending JP2019506159A (ja) | 2016-01-20 | 2017-01-20 | Ｄ因子を阻害するための組成物および方法 |
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039070A Pending JP2022078283A (ja) | 2016-01-20 | 2022-03-14 | Ｄ因子を阻害するための組成物および方法 |
| JP2023220791A Pending JP2024029136A (ja) | 2016-01-20 | 2023-12-27 | Ｄ因子を阻害するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10174325B2 (enExample) |
| EP (1) | EP3405577B8 (enExample) |
| JP (3) | JP2019506159A (enExample) |
| CN (1) | CN108934169A (enExample) |
| AU (3) | AU2017210042B2 (enExample) |
| CA (1) | CA3011819A1 (enExample) |
| GB (1) | GB2553252B (enExample) |
| WO (1) | WO2017127761A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3110419A4 (en) | 2014-02-25 | 2017-07-26 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of complement mediated disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018136831A1 (en) * | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| CN113195472A (zh) | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
| WO2020146731A1 (en) * | 2019-01-11 | 2020-07-16 | Drive Therapeutics Llc | Compositions and methods for inhibiting vascular endothelial growth factor |
| MX2021011507A (es) | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
| MX2022004939A (es) * | 2019-10-23 | 2022-08-10 | Gemini Therapeutics Sub Inc | Metodos para tratar pacientes que tienen mutaciones de cfh con proteinas de cfh recombinantes. |
| CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
| JP7829595B2 (ja) * | 2021-04-09 | 2026-03-13 | 武田薬品工業株式会社 | 補体因子ｄを標的とする抗体及びその使用 |
| CN121969751A (zh) * | 2023-10-11 | 2026-05-01 | 瑞泽恩制药公司 | 使用补体因子d (cfd)抑制剂治疗黄斑变性 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| WO1998055471A1 (en) | 1997-06-03 | 1998-12-10 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
| WO1999027133A1 (en) | 1997-11-26 | 1999-06-03 | Medical Research Council | Improved selex procedure and an anti-cd4 aptamer |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| EP1594541A4 (en) | 2003-02-21 | 2007-03-28 | Rikshospitalet Radiumhospitale | METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP1861114B1 (en) | 2005-03-11 | 2011-02-02 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| KR101126423B1 (ko) | 2005-10-21 | 2012-07-11 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 보체 활성화를 억제하는 변형된 프로테아제 |
| DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| AU2006337093B2 (en) | 2005-12-22 | 2013-03-14 | Opko Pharmaceuticals, Llc. | Compositions and methods for regulating complement system |
| JP2009521506A (ja) | 2005-12-22 | 2009-06-04 | アルコン リサーチ， リミテッド | 補体因子ｈの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのｃ３コンバターゼインヒビター |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| US8790924B2 (en) | 2006-10-19 | 2014-07-29 | Duke University | Reversible platelet inhibition |
| CN106084055A (zh) | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| EP2148691B1 (en) | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
| RU2009144142A (ru) * | 2007-04-30 | 2011-06-10 | Алькон Рисерч, Лтд. (Us) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| US8981060B2 (en) | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| GB0718737D0 (en) | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| CA2707859A1 (en) | 2007-12-11 | 2009-06-18 | Glaxo Group Limited | Antigen binding proteins specific against beta amyloid |
| CA2718588A1 (en) | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| US8940299B2 (en) | 2008-02-28 | 2015-01-27 | Case Western Reserve University | Method of treating cancer |
| DK2262831T3 (en) | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| US8664362B2 (en) | 2008-03-03 | 2014-03-04 | NovelMed Therapeutics | Humanized and chimeric anti-properdin antibodies |
| WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| EP2159286A1 (en) | 2008-09-01 | 2010-03-03 | Consiglio Nazionale Delle Ricerche | Method for obtaining oligonucleotide aptamers and uses thereof |
| WO2010030789A1 (en) | 2008-09-10 | 2010-03-18 | Novelmed Therapeutics, Inc. | Device and method for inhibiting complement activation |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| US9382544B2 (en) | 2009-05-15 | 2016-07-05 | Nec Solution Innovators, Ltd. | Aptamer that recognizes peptide |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| WO2011007876A1 (ja) | 2009-07-16 | 2011-01-20 | Ｎｅｃソフト株式会社 | Ｈｍｇｂ１結合核酸分子およびその用途 |
| US20120190578A1 (en) | 2009-08-06 | 2012-07-26 | Washington University | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes |
| US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
| KR20130130732A (ko) | 2010-11-01 | 2013-12-02 | 제넨테크, 인크. | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 |
| CN103402996B (zh) | 2011-01-04 | 2015-02-11 | 诺瓦提斯公司 | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| US10966945B2 (en) | 2011-08-01 | 2021-04-06 | Aurin Biotech Inc. | Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex |
| EP2762569B1 (en) | 2011-09-28 | 2018-06-13 | RIBOMIC Inc. | Ngf aptamer and application thereof |
| MX355567B (es) | 2011-12-30 | 2018-04-23 | Quest Diagnostics Invest Inc | Aptameros y metodos de diagnostico para detectar el receptor de egf. |
| ES2749624T3 (es) | 2013-03-14 | 2020-03-23 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| EP3110419A4 (en) | 2014-02-25 | 2017-07-26 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of complement mediated disorders |
| SG11201608868PA (en) * | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| TWI623617B (zh) | 2014-08-29 | 2018-05-11 | 國立清華大學 | 對卵巢癌具有專一性之適合體及其應用 |
| JP2018535679A (ja) | 2015-11-19 | 2018-12-06 | ベース ペア バイオテクノロジーズ，インク． | 標的分子の高感度検出のための方法及び材料 |
| WO2017127762A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Methods for improved aptamer selection |
| EP3405577B8 (en) | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| EP3414330A4 (en) | 2016-02-08 | 2019-07-03 | Vitrisa Therapeutics, Inc. | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF |
| WO2018136831A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Pseudoknot compositions and methods for inhibiting factor d |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2019022986A1 (en) | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
-
2017
- 2017-01-20 EP EP17742071.8A patent/EP3405577B8/en active Active
- 2017-01-20 CA CA3011819A patent/CA3011819A1/en active Pending
- 2017-01-20 CN CN201780018764.5A patent/CN108934169A/zh active Pending
- 2017-01-20 JP JP2018538551A patent/JP2019506159A/ja active Pending
- 2017-01-20 WO PCT/US2017/014458 patent/WO2017127761A1/en not_active Ceased
- 2017-01-20 GB GB1718801.2A patent/GB2553252B/en active Active
- 2017-01-20 AU AU2017210042A patent/AU2017210042B2/en active Active
- 2017-08-31 US US15/693,361 patent/US10174325B2/en active Active
-
2018
- 2018-09-04 US US16/121,458 patent/US20190161755A1/en not_active Abandoned
-
2020
- 2020-01-14 US US16/742,741 patent/US11274307B2/en active Active
-
2021
- 2021-04-20 AU AU2021202392A patent/AU2021202392B2/en active Active
-
2022
- 2022-03-14 JP JP2022039070A patent/JP2022078283A/ja active Pending
-
2023
- 2023-04-27 AU AU2023202548A patent/AU2023202548A1/en not_active Abandoned
- 2023-12-27 JP JP2023220791A patent/JP2024029136A/ja active Pending
-
2024
- 2024-07-05 US US18/765,089 patent/US20250197868A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Motib et al. | Modulation of quorum sensing in a gram‐positive pathogen by linear molecularly imprinted polymers with anti‐infective properties | |
| JP2011515073A5 (enExample) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2008140653A3 (en) | Humaneered anti-factor b antibody | |
| MX2020000435A (es) | Anticuerpos anti-cd166 y usos de estos. | |
| UY28641A1 (es) | Anticuerpos | |
| BR0211953A (pt) | Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb | |
| AR046682A1 (es) | Terapia de combinacion para tratamiento de desordenes neovasculares oculares | |
| NZ600348A (en) | Anti-c5a binding moieties with high blocking activity | |
| DK1819830T3 (da) | Fremgangsmåder til antistofgenerering | |
| JP2017507657A5 (enExample) | ||
| RU2010138612A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR | |
| JP2018198596A5 (enExample) | ||
| NZ591633A (en) | Combination gas vaccines and therapeutics | |
| PL1699826T3 (pl) | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność | |
| WO2009028880A3 (en) | Biomarker composition for detecting diabetic retinopathy and diagnostic kit therefor | |
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| CN115768476A (zh) | 抗il-17a抗体药物组合物及其用途 | |
| WO2004075838A3 (en) | Method and compositions for the treatment of meconium aspiration syndrome | |
| WO2013177035A3 (en) | Humaneered anti-factor b antibody | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| JP2022119899A5 (enExample) | ||
| ATE502050T1 (de) | Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin | |
| WO2006059247A3 (en) | VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC | |
| ATE477274T1 (de) | Gegen clostridium difficile gerichtete antikörper |